BAM
REGN icon

Bruderman Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bruderman Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-317
Closed -$130K – 456
2019
Q1 		$130K Hold
317
– – 0.03% 158
2018
Q4 		$118K Buy
+317
New +$116K 0.03% 156

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bruderman Asset Management's REGN Position: Q2 2019 in Review

Bruderman Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2019, closing a stake of 317 shares — an estimated $130K sold.

Bruderman Asset Management first reported a position in REGN in Q4 2018 and held it in 2 quarters. The position peaked at $130K in Q1 2019. 658 funds tracked by Wall St. Rank hold REGN as of Q2 2019.

  • Bruderman Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Bruderman Asset Management sold 317 Regeneron Pharmaceuticals shares in Q2 2019, an estimated $130K.
  • Bruderman Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Bruderman Asset Management's Regeneron Pharmaceuticals position peaked at $130K in Q1 2019.
  • 658 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2019.

Based on Bruderman Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.